Benzinga | Dec 4, 2020 07:36AM EST

Cellular Biomedicine Group Highlights Data To Be Presented At American Society Of Hematology Dec. 5-8

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that three abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held as a virtual event on December 5-8, 2020.





Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

C-CAR088

Abstract Title: An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma

Date: Saturday, December 5, 2020

Time: 1:15pm PST

Abstract Online: https://ash.confex.com/ash/2020/webprogram/Paper138734.html

A copy of the presentation materials will be made available on the Investor Relations section of the Company website following the presentation.

C-CAR039

Abstract Title: Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

Online only: https://ashpublications.org/blood/article/136/Supplement%201/8/473629/Developing-a-Novel-Anti-CD19-CD20-Bi-Specific

C-CAR066

Abstract Title: Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

Online only: https://ashpublications.org/blood/article/136/Supplement%201/8/473636/Early-Clinical-Results-of-a-Novel-Anti-CD20